TransCode Therapeutics reports Phase 1a trial of TTX-MC138 meets safety endpoint in metastatic cancer
PUBT · 06/03 12:07
Share
Listen to the news
- TransCode Therapeutics completed a Phase 1a dose-escalation trial of TTX-MC138 in metastatic cancer, clearing its safety objective.
- Patients generally tolerated treatment, with no dose-limiting toxicities reported, supporting a move into Phase 2a development.
- Several participants achieved durable disease stabilization, including some who remain on therapy.
- Future scientific congress presentations are planned; a clinical study report is being prepared.
- Phase 2a will evaluate TTX-MC138 in ctDNA-positive colorectal cancer following curative-intent therapy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE74261) on June 03, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved